Cambridge Researchers Test AI-Designed Coronavirus Vaccine in Early Human Trial
The vaccine was safe in 39 healthy volunteers and triggered immune responses to SARS-CoV-2, SARS and related bat viruses, researchers said.
- Researchers at the University of Cambridge and DIOSynVax developed an AI-designed 'super-antigen' vaccine offering protection against entire families of viruses rather than just specific strains.
- Artificial intelligence analyzed genetic codes from various coronaviruses to identify essential, unchanging elements across virus families, creating a 'fundamentally new' approach that future-proofs against mutations.
- A phase I trial in Cambridge and Southampton involving 49 healthy volunteers aged 18 to 50 confirmed the vaccine is safe and triggered immune responses against SARS-CoV-2, SARS, and related bat viruses.
- More than 200 individuals will be recruited for a forthcoming phase II study, with Professor Jonathan Heeney calling the technology a 'game changer' for vaccine development.
- Scientists are now exploring applications for other virus families, including Ebola and bird flu, aiming to prevent pandemics before they start and potentially save millions of lives.
87 Articles
87 Articles
Researchers Successfully Trial AI-Designed Vaccine for the First Time
The researchers used machine learning on genetic sequence data to design a super-antigen containing features common across the entire sarbecovirus group, which includes the viruses responsible for SARS and Covid-19.
World’s First AI-Designed Vaccine Tested in Humans Could Fight Future Pandemics
Coronavirus vaccine. Credit: Public domain Researchers have developed an AI-designed vaccine that could protect against a broad range of coronaviruses, including future strains that have not yet emerged. Scientists at the University of Cambridge say the project marks the first time an Artificial Intelligence-designed vaccine antigen has been tested in human volunteers. They believe the technology could eventually help protect against entire fami…
Computer-designed universal vaccine shows early human trial success
A Cambridge-led team has developed an early-stage vaccine platform that uses computational design to generate broad immune protection against entire virus families, with the aim of reducing the need to repeatedly update vaccines as viruses mutate. The approach, developed by researchers at the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has now reached a key milestone after its first human clinical trial showed safety and immune res…
Artificial intelligence has helped create a completely new type of vaccine that in the future could protect not only against all strains of coronaviruses, but also against viruses that are not yet known. The vaccine has already been tested in humans.
Coverage Details
Bias Distribution
- 41% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
